Latest news with #GHO
Yahoo
14-07-2025
- Business
- Yahoo
AAVE Surges as Deposits Hit $50B; Poised to Benefit From U.S. Crypto Regulation
Native token of decentralized finance (DeFi) lending platform Aave AAVE surged to its strongest price in several months on Monday The bluechip DeFi token topped $330 during the session before cooling off at $316, gaining 8% over the weekend. The rally came as the DeFi sector is heating up amid a broader crypto rally, with bitcoin BTC conquering fresh records above $120,000. Aave is the dominant player in DeFi lending, and has just hit $50 billion in deposits on the protocol, a fresh record level. The platform also poised to be one of the biggest gainers of advancing U.S. crypto regulations, analysts said. "Aave is the biggest lending platform in decentralized finance (DeFi), and it could be a major winner from the GENIUS Act," digital asset manager 21Shares said in a Monday report. The platform currently holds 5% of all stablecoin supply to earn a yield, more than any other DeFi protocol, the report noted. It also issues its own, overcollateralized stablecoin GHO GHO, which has a $312 million supply. Aave also aim to benefit from the growing institutional participation and tokenization wave with the upcoming Horizon project that will let institutions borrow stablecoins by posting tokenized real-world assets such as money market funds as collateral, the report added. CoinDesk's market analytics model highlighted a bullish structure for AAVE. Trading volume spikes to 159,078 units during morning session, confirming institutional accumulation and sustained buying pressure. Support base forms at $304.25-$305.63 during initial decline, providing foundation for subsequent rally phase. Resistance cluster develops around $327.40 where multiple rejection attempts create volume-weighted ceiling. Psychological support at $320.00 attracts consistent demand throughout consolidation period. Sign in to access your portfolio
Scoop
16-06-2025
- Politics
- Scoop
Brutal Cuts Mean Brutal Choices Warns UN Relief Chief, Launching ‘Survival Appeal'
16 June 2025 'We have been forced into a triage of human survival,' said Mr. Fletcher. 'The math is cruel, and the consequences are heartbreaking. Too many people will not get the support they need, but we will save as many lives as we can with the resources we are given.' New priorities The appeal aims to reprioritise individual country plans in pursuit of two main goals: first, to reach people and places facing the most urgent humanitarian needs, and second, to prioritise life-saving support based on existing planning for the 2025 humanitarian response. This is intended to ensure that limited resources are directed where they can do the most good, as quickly as possible. Rather than limiting lifesaving aid to a predetermined matrix, humanitarian partners are focused on addressing the most urgent needs in ways that respect the dignity of affected people, allowing them to choose what they need most, OCHA said. The appeal prioritises but does not replace the Global Humanitarian Overview 2025 (GHO), launched last December, which covers 180 million vulnerable people across 70 countries. The GHO calls for $44 billion, but at the halfway point of the year, less than 13 per cent of that amount has been received. A call for global solidarity 'Brutal funding cuts leave us with brutal choices,' said Fletcher. 'All we ask is one per cent of what you chose to spend last year on war. But this isn't just an appeal for money – it's a call for global responsibility, for human solidarity, for a commitment to end the suffering.'
Yahoo
31-05-2025
- Business
- Yahoo
AAVE Rebounds From 15% Drop as DeFi Yield Markets Gain Momentum
AAVE has demonstrated remarkable resilience in the face of global market turbulence, rebounding from a 15% price drop over four days as buyers stepped in to capitalize on DeFi's growing momentum. The protocol's price climbed from $240 to above $250, buoyed by expanding tokenized yield markets that are drawing increased institutional and retail interest. The price action comes as global trade tensions and new tariff uncertainties — including reports of China violating its trade agreement with the U.S. — injected volatility across risk assets. Despite these headwinds, the DeFi sector is showing renewed strength, with total value locked (TVL) surging to $178.52 billion. AAVE remains a key leader in the space, commanding a TVL of $25.41 billion. News Background A key driver of AAVE's recent rebound has been its integration with Pendle's tokenized yield markets, which saw new markets reach their supply caps within hours of launch, underscoring the strong demand for yield-generating products in the DeFi ecosystem. The Ethereum Foundation (EF) borrowed $2 million in GHO, Aave's decentralized stablecoin pegged to the U.S. Dollar, earlier this week. This move, facilitated by supplying ETH as collateral, highlighted EF's strategy of leveraging its crypto holdings to fund operations while supporting Aave's protocol. Aave's GHO stablecoin is fully overcollateralized within the Aave ecosystem, with EF's loan backed by 1,403,519.94 Gwei of ETH (valued at $0.01 in the transaction). Interest payments on this loan support Aave's DAO treasury, reinforcing a community-driven financial model that incentivizes participation and governance. Aave's lending dominance is underscored by its 45% market share from January 2023 to May 2025, according to IntoTheBlock data. This figure highlights Aave's steady recovery from the 2023 DeFi dip and cements its status as the largest decentralized lending protocol by volume and activity. Technical Analysis Recap AAVE established a high-volume support zone around $242.70 during the 16:00-17:00 and 01:00-02:00 hours, attracting strong buying with volumes exceeding 90,000 units. A bullish ascending triangle pattern formed, with higher lows indicating accumulation despite recent resistance. After peaking at $255.96 at 20:00, AAVE set resistance at $253.75 before stabilizing at $248-$250. A notable volume spike between 07:51-07:52 coincided with a sharp rise from $248.98 to $249.82, creating a new resistance level. A cup-and-handle pattern formed, with the handle developing between 07:56-08:00, suggesting accumulation after the recent pullback. Short-term consolidation near $249, coupled with increasing volume on upward moves, hints at potential bullish momentum building for a test of $250 resistance. As DeFi yield markets continue to expand, AAVE's ability to integrate new products and sustain high-volume support levels positions it as a key player in the sector's growth — despite the broader market's macroeconomic challenges. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-02-2025
- Business
- Yahoo
Jan De Witte joins GHO Capital as Operating Partner
Jan De Witte joins GHO Capital as Operating PartnerLondon, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ('GHO'), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences ('Integra', NASDAQ: IART), a global leader in regenerative tissue technologies, and neurosurgical and ENT solutions. At Integra Jan drove international expansion and operational excellence, and through strategic acquisitions and innovation added $1 billion to the total addressable market of the company's offerings. Prior to Integra, Jan served as CEO of Barco N.V. (EBR: BAR), directing the advanced visualisation technology company's digital transformation and global market expansion. He strengthened Barco's position in the healthcare, entertainment, and enterprise sectors through new product launches and operational improvements and global market expansions. Earlier in his career, he spent 18 years at GE Healthcare leading global teams in Digital Health, Services, Manufacturing, Quality and Supply Chain across the Americas, EMEA, and Asia. Jan's career started with foundational roles in Operations at Procter & Gamble and as Senior Consultant at McKinsey in Europe. Jan currently serves as a Director of ResMed Inc. (NYSE: RMD), a digital health and medical device leader. His board experience includes previous roles at Barco N.V. and international joint ventures. He holds an M.B.A. from Harvard Business School and Master's and Bachelor's degrees in electromechanical engineering with highest distinction from KU Leuven, Belgium. As Operating Partner, Jan will leverage his extensive leadership experience and global network to support and grow GHO's portfolio companies, as well as supporting with the firm's transatlantic deal origination. The Partners at GHO Capital commented: 'Jan brings a wealth of healthcare industry expertise and a strong track record to our team as we look to implement our proven operational playbook and drive expansion and growth across our portfolio. The healthcare sector is experiencing significant innovation, supported by favourable market conditions, and Jan's experience will help us identify businesses with the most substantial growth potential. On behalf of the entire GHO team, we warmly welcome him and look forward to the positive impact he will make.' Commenting on his new appointment, Jan De Witte, Operating Partner at GHO Capital, said: 'My focus throughout my career has always been to support innovative healthcare companies as they grow and transform, whilst creating long-term investor value. I am excited to be joining GHO Capital, one of Europe's leading healthcare specialist private equity firms, who are committed to driving the highest standards across the healthcare sector. I look forward to working with the team and leveraging my expertise to support GHO's portfolio companies realise their full potential.' -Ends- Further information: GHO Capital Partners LLP T +44 20 3700 7440 E IR@ For Media EnquiriesICR HealthcareAmber Fennell, Angela Gray, Kris Lam Tel: +44 (0) 20 3709 5700ghocapital@ About GHO Capital Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital's proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit in to access your portfolio
Yahoo
05-02-2025
- Business
- Yahoo
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners ('Ampersand'), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices ('Avid' of the 'Company'), a dedicated biologics Contract Development and Manufacturing Organisation ('CDMO') working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies. Avid has experienced significant growth in recent years, offering its clients full lifecycle capabilities—from concept to commercial supply. With substantial investment already made by the Company in its capacity at its state-of-the art facilities and its expertise in bioprocess optimisation, analytical testing, and regulatory compliance, Avid delivers high-quality, industry leading complex biologics to a roster of international customers. GHO has considerable expertise in the CDMO sector through investments in its portfolio in companies like Ardena, Sterling Pharma Solutions, RoslinCT, and Alcami Corporation. Its strategy focuses on expanding technological capabilities, driving acquisitions, and supporting transatlantic expansion across the CDMO value chain, from early-stage development to commercial manufacturing. Leveraging its healthcare expertise and network, GHO Capital transforms CDMOs to enhance their services and market reach, ultimately delivering better, faster and more accessible healthcare. Alan MacKay and Mike Mortimer, Managing Partners of GHO, commented: 'We are delighted to start 2025 with the completion of this transaction, our first public to private deal. GHO has a deep understanding of the CDMO sector and Avid perfectly exemplifies a company that is operating in high growth markets supporting the growing biotech sector in research and development and big pharma and large biotech for the commercialisation of cutting-edge biologics. Avid's recent investments, both in capacity and its exemplary team, have created a strong foundation for future growth. We look forward to partnering closely with the Avid team to unlock the business's full potential.' Nick Green, President and CEO of Avid, said: 'Avid has succeeded by evolving and adapting to meet our customers' complex development and manufacturing needs. The completion of this transaction marks an exciting milestone as we move forward with new owners in GHO Capital and Ampersand who will provide us with access to resources that will accelerate our growth. With their support, we are well-positioned to enhance our capabilities, expand our service offerings, and deliver even greater value to our customers in this next phase of our journey." David Anderson, General Partner of Ampersand, added: 'Avid has earned its reputation as a leader in biopharmaceutical development and manufacturing through technical excellence, customised solutions, and consistent regulatory compliance. By combining our deep industry expertise with Avid's established capabilities, we are positioned to deliver enhanced value and accelerate innovation for clients globally.' On 7 November 2024, GHO and Ampersand entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1 billion. With the completion of the transaction, Avid's stockholders are entitled to receive $12.50 per share in cash. The Company's common stock has ceased trading and will be delisted from Nasdaq. AdvisorsWilliam Blair served as buyside financial advisers, Ropes & Gray served as legal counsel, ClearView Healthcare Partners served as commercial advisor and Alvarez & Marsal served as financial advisors to GHO and Ampersand. Contacts: GHO Capital Amber Fennell / Kris LamICR Healthcare+44 7739658783ghocapital@ Avid Bioservices Stephanie DiazVida Strategic Partners415-675-7401sdiaz@ Tim BronsVida Strategic Partners415-675-7402tbrons@ Aaron Palash / Allison SobelJoele Frank, Wilkinson Brimmer Katcher(212) 355-4449 About GHO Capital Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital's proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit About Avid Bioservices, Inc. Avid Bioservices is a dedicated CDMO focused on development and CGMP manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. About Ampersand Capital Partners Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn.
